Agreement increases Hormonal Therapies reach across EU

Pharmaceutical organisation Diurnal Group has extended its agreement with Er-Kim for the distribution and marketing of its encapsulated hydrocortisone granules targeting chronic endocrine (hormonal) diseases, in Greece, Cyprus and Malta.

 The combined market opportunity for these three countries has been estimated to be approximately €7m in paediatric adrenal insufficiency (AI) and adult congenital adrenal hyperplasia (CAH). Er-Kim already holds distribution and marketing rights for supplying these products to Turkey, Romania and Bulgaria.

Diurnal’s licensed preparation of hydrocortisone, Alkindi®, approved in the UK, the European Economic Area, Israel, Australia, Switzerland and the US, is specifically designed for use in children suffering from AI, including the related CAH.  

The company’s Efmody® is a modified-release preparation of hydrocortisone for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes. In May 2021, this was granted marketing authorisation in the European Union and was launched by the Company in Germany, Austria and the UK during September that year.

Richard Bungay, Interim Chief Executive Officer and Chief Financial Officer of Diurnal, commented:

“Following this latest agreement with Er-Kim, we are pleased that the Company’s commercial footprint now reaches 70% of the European Union population.”

Cem Zorlular, Chairman and Chief Executive Officer of Er-Kim, said:

“We are pleased to expand our collaboration with Diurnal after a year of working relentlessly to execute on our shared vision of addressing unmet rare endocrine conditions in Turkey, Romania and Bulgaria. We are very excited to have the opportunity to now provide market access to much needed paediatric and adult cortisol deficiency treatments in Greece, Malta, Cyprus.”

More information online